AIMZ Investment Advisors LLC Reduces Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

AIMZ Investment Advisors LLC lessened its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 225,957 shares of the company’s stock after selling 617 shares during the quarter. Teva Pharmaceutical Industries comprises approximately 1.2% of AIMZ Investment Advisors LLC’s portfolio, making the stock its 28th biggest holding. AIMZ Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $3,473,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Golden State Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $39,000. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at $43,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $44,000. Compagnie Lombard Odier SCmA bought a new position in shares of Teva Pharmaceutical Industries in the first quarter worth $54,000. Finally, Banque Cantonale Vaudoise purchased a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at $74,000. Institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

TEVA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. Finally, UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $24.71.

Teva Pharmaceutical Industries Trading Down 1.8%

Shares of TEVA opened at $18.4660 on Friday. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a market capitalization of $21.18 billion, a P/E ratio of -115.41, a P/E/G ratio of 1.09 and a beta of 0.62. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm’s 50 day simple moving average is $16.75 and its 200 day simple moving average is $16.27.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business’s revenue for the quarter was up .3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Matthew Shields sold 6,206 shares of the firm’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 65,001 shares of company stock valued at $996,958 over the last 90 days. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.